Login to Your Account

NewCo News

Orphagen Seeks Ligands for Orphan Nuclear Receptors

By Trista Morrison
Staff Writer

Tuesday, May 22, 2012
Orphagen Pharmaceuticals Inc. knows its orphan nuclear receptor programs are too early stage for most venture capitalists. In fact, they're too early even for most academics, CEO Scott Thacher told BioWorld Today.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription